Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in france: real world data from the permanent sample of national health insurance beneficiairies.
CONCLUSIONS: This analysis of real-world data confirms the poor prognosis of patients with R/M SCCHN and provides cost data for future economic evaluations. PMID: 30895832 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 23, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The importance of accounting for the uncertainty around the preference-based health-related quality of life measures value sets: a systematic review.
Authors: Kharroubi SA, Beyh Y Abstract Preference-based measures of health-related quality of life including, but not limited to, the EQ-5D, HUI2 and the SF-6D have been increasingly used in calculations of quality-adjusted life years for cost effectiveness analyses. However, the uncertainty around the measures' value sets is commonly ignored in economic evaluation. There are several types of uncertainties including methodological, structural, and parameter uncertainties, with the latter being the focus of this review paper. Our objective is to highlight the gap in the literature regarding the existence of uncertai...
Source: Journal of Medical Economics - March 9, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.
Authors: Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S Abstract AIMS: To examine healthcare resource utilization associated with refractory myasthenia gravis (MG) in England. MATERIALS AND METHODS: This was a retrospective cohort study of linked data from the Clinical Practice Research Datalink and the Hospital Episode Statistics database collected between 1997 and 2016. Included patients were ≥18 years of age at the index MG diagnosis. Patients with refractory MG were identified using an algorithm based on treatments received. Healthcare resource utilization since the index date was compared between...
Source: Journal of Medical Economics - March 9, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Bias-corrected estimates of reduction of post-surgery length of stay and corresponding cost savings through the widespread national implementation of fast-tracking after liver transplantation: a quasi-experimental study.
This study evaluated the reduction in post-operative length of stay (LOS) that resulted from the fast-tracking protocol and assessed the potential cost saving in the case of nationwide implementation. METHODS: A propensity score for fast-tracking was generated based on MCF liver transplant databases during 2011-2013. Various propensity score matching algorithms were used to form control groups from the United Network of Organ Sharing Standard Analysis and Research (STAR) file that had comparable demographic characteristics and health status to the treatment group identified in MCF. Multiple regression and matching esti...
Source: Journal of Medical Economics - March 9, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina.
CONCLUSIONS: Over the next five years, approximately 4,485,352 fractures are anticipated to occur in Brazil, Mexico, Colombia, and Argentina. To control and prevent these fractures, stakeholders must work together to close the care gap. Efforts to identify individuals at high fracture risk, initiate treatment, and improve long-term treatment persistence will be essential in minimizing the financial and patient burden of osteoporosis in Latin America. PMID: 30835577 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
CONCLUSION: Atezolizumab represents a cost-effective therapeutic option in Canada for the treatment of patients with advanced NSCLC who progress after first-line platinum doublet chemotherapy. PMID: 30836031 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Migraine burden and costs in france: a nationwide claims database analysis of triptan users.
Authors: Donnet A, Emery C, Aly S, Allaf B, Cayre F, Mahieu N, Gourmelen J, Levy P, Fagnani F Abstract OBJECTIVES: To estimate the burden of migraine in the population of French patients identified as specific migraine acute treatment users as compared to a control group. METHODS: A cross-sectional retrospective analysis was performed on the "Echantillon Généraliste des Bénéficiaires" claims database, a 1/97 random sample of the French public insurance database. A representative sample of all adults with at least one delivery of triptans, ergot derivatives or acetylsalicyli...
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
CONCLUSIONS: Over 50% of Medicare patients with mUC received no chemotherapy. Among chemotherapy-treated patients, most received only one LOT. Additional LOTs led to higher mean costs and HCRU, but as patients were followed longer, monthly costs decreased. As treatments evolve to include immuno-oncology agents, these findings provide a clinically-relevant economic benchmark for mUC treatment across different traditional LOTs. PMID: 30836812 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model.
CONCLUSIONS: The model results suggest improved intraoperative hypotension control in a hospital with annual volume 10,000 non-cardiac surgical patients is associated with mean cost reductions ranging from $1.2 to $4.6 million per year. Since the magnitude of the RCT mean estimate is similar to the unadjusted observational model, the institutional costs are likely at the upper end of this range. PMID: 30838899 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Modeling operational quality metrics and costs of long-acting antibiotics for ABSSSI treatment in the emergency department.
CONCLUSIONS: LA pathway implementation for ABSSSI treatment in the ED supported improved efficiency, which may translate to economic value. As EDs continue to focus on improving key metrics such as throughput rate and LOS, LA pathway implementation should be considered as a potential approach for abbreviated ABSSSI treatment in the ED. PMID: 30838908 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
CONCLUSIONS: ESA-treated patients undergoing dialysis incurred lower costs, lower HRU, and had better HRQoL relative to ESA-untreated patients. However, treatment to higher Hb targets led to modest HRQoL improvements compared to lower Hb targets. PMID: 30813807 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 4, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analyses using real-world data: an overview of the literature.
CONCLUSIONS: RWE is likely to be particularly valuable for informing healthcare policy-makers when formulating appropriate treatment pathways, encouraging the optimal allocation of scarce resources, and improving aggregate patient outcomes. However, little guidance is available on the relative merits of using efficacy and/or effectiveness evidence in Health Technology Appraisal submissions. Further research is needed to better understand these methods and their potential applications in a broader range of scenarios and simulation studies, and their impact on economic modeling. PMID: 30816067 [PubMed - as supplied by pu...
Source: Journal of Medical Economics - March 4, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Correction.
Authors: Grosse SD, Krueger KV, Pike J PMID: 30821543 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 4, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
CONCLUSION: It is recommended that the price of utidelone would be less than $18.5 per 30mg in order to obtain cost-effectiveness for metastatic breast cancer patients resistant to anthracyclines and taxanes treatment in China. PMID: 30808230 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 28, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Psychiatric inpatient cost of care before and after admission at a residential subacute step-up/step-down mental health facility.
This study aims to examine psychiatric inpatient admissions, length of stay and per capita cost of care following the establishment of a step-up/step-down Prevention And Recovery Care (PARC) facility in regional Australia. METHODS: Pragmatic before and after study set within a participatory action research methodology. The target sample comprised patients at a PARC facility over 15 months. Six-month individual level data prior to study entry, during, and over six months from study exit were examined using patient activity records. Costs were expressed in 2015-16AU$. RESULTS: An audit included 192 people experiencin...
Source: Journal of Medical Economics - February 28, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML).
Authors: Matza LS, Deger KA, Howell TA, Koetter K, Yeager AM, Hogge D, Fisher V, Louie AC, Chung KC Abstract Aims Acute myeloid leukemia (AML) treatment typically involves remission induction chemotherapy followed by consolidation chemotherapy. New treatments for AML have recently been introduced, including a chemotherapy formulation called CPX-351, which is administered via less time-intensive IV infusion than the standard "7 + 3" continuous infusion regimen of cytarabine plus an anthracycline. The purpose of this study was to estimate utilities that could be used in economic modeling of AM...
Source: Journal of Medical Economics - February 20, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis.
Conclusions UF is a viable alternative to DIUR-T when treating fluid overload in HF patients because it reduces hospital readmission rates and durations, which substantially lowers costs over a 90-day period compared to DIUR-T. PMID: 30775944 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 20, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures: a retrospective model based cost analysis.
CONCLUSIONS: TYRX would be a cost-saving treatment option amongst heart failure patients undergoing ICD and CRT device procedures based on analysis in the local geographical area of South London. If upscaled to the UK population, we estimate potential cost savings for the National Health Service (NHS). PMID: 30744444 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 14, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Does the critical illness insurance reduce patients' financial burden and benefit the poor more: a comprehensive evaluation in rural area of China.
Authors: Jiang J, Chen S, Xin Y, Wang X, Zeng L, Zhong Z, Xiang L Abstract BACKGROUND: Critical illness insurance (CII) is one kind of health insurance that is gradually gaining attention worldwide. China implemented CII in 2012 to decrease patients' out-of-pocket (OOP) medical payments. The aims of this study were to determine if the project had positive impacts on relieving financial burden and improving health equity. METHODS: A series of questionnaire surveys were undertaken in two counties before and after the intervention in rural China. OOP expenditure, catastrophic Health Expenditure (CHE) incidence and...
Source: Journal of Medical Economics - February 14, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance.
CONCLUSION: Despite warfarin being significantly less expensive to purchase than NOACs, overall warfarin management incurs higher costs due to laboratory monitoring and provider time than NOACs. NOAC treatment, therefore, may not be more expensive than warfarin therapy management for complex anticoagulation patients. PMID: 30744455 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 14, 2019 Category: Health Management Tags: J Med Econ Source Type: research

CAR T-cells: Costs, Comparisons and Commentary.
Authors: Hay AE, Cheung MC PMID: 30747012 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 14, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The whole is greater than the sum of its parts: the importance of integrated, universal and equitable healthcare coverage.
Authors: Petrou P Abstract Universal Health Coverage entails a universal, equitable and effective provision of comprehensive health services. In this context, socioeconomic attributes have acquired a dominant role as determinants in healthcare coverage. This violates equity, the principal attribute of a health system and creates fragmented pools of patients, thus impeding risk distribution. Inequity may expose patients to steep out-of-pocket payments or hinder their access to the necessary medical care. A shift to universal and equitable healthcare coverage is imperative. PMID: 30757933 [PubMed - as supplied by...
Source: Journal of Medical Economics - February 14, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
Conclusion Some components of public HTA may be relevant for private payers, however there are reservations that still exist on whether the HTA process in Canada, designed for a public system, can address the informational needs of private payers. Private insurers need to use caution in assessing which value parameters from public HTAs can be used and which need to be confirmed, ignored, enhanced, or adjusted. One size HTA does not fit all applications. PMID: 30757934 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 14, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
Authors: Lage MJ, Boye KS, Bae JP, Wu J, Mody R, Botros FT Abstract AIMS: Examine healthcare costs across chronic kidney disease (CKD) stages for US patients with type 2 diabetes (T2D). MATERIALS AND METHODS: IQVIA Real World Data Adjudicated Claims linked electronic medical records and insurance claims from January 1, 2012 through March 31, 2017 were used for this retrospective study. Adults diagnosed with T2D and comorbid CKD were included. General linear models incorporating splines were constructed and information from these regressions were used to inform the relationship between medical costs and CKD. Mul...
Source: Journal of Medical Economics - February 11, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
CONCLUSION: As the first-line treatment for schizophrenia in China, olanzapine-ODT is cost-effective compared to olanzapine-SOT and olanzapine-SOT is cost-effective compared to aripiprazole-SOT. PMID: 30732487 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 10, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-impact of cardiac magnetic resonance imaging with Fast-SENC compared to SPECT in the diagnosis of coronary artery disease in the U.S.
CONCLUSION: The lower cost, higher sensitivity and specificity rates, and faster, less burdensome process for detecting CAD patients make Fast-SENC a more capable and economically beneficial stress test than SPECT. The payer model and hospital model demonstrate an alignment between payer and provider economics as Fast-SENC provides monetary savings for patients and resource benefits for hospitals. PMID: 30732489 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 10, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.
The objective of this study was to measure the impact of copay assistance on patient cost sharing and treatment patterns in patients prescribed oral ALK inhibitors (ALKis). METHODS: Patterns of claims approval/rejection and payment/reversal, out-of-pocket (OOP) costs, and treatment persistence were reported for patients identified in the IQVIA Formulary Impact Analyzer database from January 2013 to August 2017 linked to a medical claims database. The primary study cohorts were patients with copay assistance, including manufacturer's copay cards, other discount cards, or free-trial vouchers, on the index ALKi claim and ...
Source: Journal of Medical Economics - February 8, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records.
CONCLUSION: HRS is associated with poor outcomes and high hospital costs. Analysis of HRS cost drivers demonstrated an unmet need for additional treatment options to improve outcomes in this patient population. PMID: 30724682 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilisation (HCRU) in schizophrenia.
The objective of this study was to conduct a SLR of published data on the relationship between outcomes and QoL or HCRU. MATERIALS AND METHODS: Electronic searches were conducted in Embase and Medline, for articles which reported on the association between outcomes and QoL or HCRU. Inclusion and exclusion criteria were applied to identify the most relevant articles and studies and extract their data. A summary table was developed to illustrate the strength of associations, based on p-values and correlations. RESULTS: One thousand and two abstracts were retrieved; 5 duplicates were excluded. 997 abstracts were scree...
Source: Journal of Medical Economics - February 1, 2019 Category: Health Management Tags: J Med Econ Source Type: research

A Monte Carlo simulation estimating US hospital cost reductions associated with hypotension control in septic ICU patients.
CONCLUSIONS: Hypotension control (via TWA-MAP improvements) for patients with sepsis in the ICU is associated with lower hospitalization cost. PMID: 30698059 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 1, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Reply: RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.
Authors: Gizzo S, Ferrando M, Lispi M, Ripellino C, Cataldo N, Bühler K PMID: 30691336 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 31, 2019 Category: Health Management Tags: J Med Econ Source Type: research

RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.
Authors: Lass A, Montgomery SM PMID: 30694085 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 31, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Incorporating Adherence in Cost-effectiveness Analyses of Asthma: A Systematic Review.
CONCLUSIONS: A very low number of CEA of asthma incorporated adherence in the analyses. All the CEA adjusted treatment effectiveness according to adherence levels, applied to the economic models. PMID: 30663455 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada.
CONCLUSIONS: TBS procedure was cost effective over SOC in a 15-year time horizon with quality of life gains. PMID: 30663456 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
CONCLUSION: Dapagliflozin treatment was more cost-effective compared with metformin treatment for Chinese type 2 diabetes patients. However, the findings of favorable cost-effectiveness results for dapagliflozin are largely driven by the effects of favorable weight profile on clinical, utility and costs in the Cardiff model. PMID: 30663458 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The economic burden of depression among adults with rheumatoid arthritis in the United States.
CONCLUSIONS: Our study suggested increased healthcare utilization, work productivity loss, and economic burden among RA patients due to comorbid depression. These findings emphasize the importance of managing depression and including depression as a factor when devising treatment algorithms for patients with RA. PMID: 30663460 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
CONCLUSIONS: Pembrolizumab is not likely to be cost-effective in the treatment of PD-L1 positive, NSCLC for Chinese patients. Less aggressive pricing may increase accessibility for patients in China. PMID: 30646794 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 18, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS: A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apremilast or biologics between January 1, 2014, and December 31, 2015; had 12 months of pre-index and post-index continuous enrollment in the database; and were biologic-naive. The index date was defined as the date of the first claim for apremilast or biologic and occurred between January 1, 2014, and December...
Source: Journal of Medical Economics - January 18, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Lacosamide as first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.
CONCLUSIONS: Lacosamide is a cost-effective option at a willingness-to-pay threshold of €30,000 per QALY, representing a valuable monotherapy treatment option for patients with focal epileptic seizures in the Greek setting. PMID: 30652931 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 18, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The economic burden of switching targeted disease-modifying antirheumatic drugs among rheumatoid arthritis patients.
Authors: Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, Paul D Abstract AIMS: To estimate real world healthcare costs and resource utilization of rheumatoid arthritis (RA) patients associated with targeted disease modifying anti-rheumatic drugs (tDMARD) switching in general and switching to abatacept specifically. MATERIALS AND METHODS: RA patients initiating a tDMARD were identified in IMS PharMetrics Plus health insurance claims data (2010-2016), and outcomes measured included monthly healthcare costs per patient (all-cause, RA-related) and resource utilization (inpatient stays, outpatient visi...
Source: Journal of Medical Economics - January 18, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.
CONCLUSIONS: The administration of intravenous or subcutaneous PIs to treat MM in health care facilities causes significant and potentially avoidable health care, travelling and indirect costs and they should be included in all health economic evaluations (HEEs). As the cost estimates utilized in this study represent most of central hospitals in the country, they provide useful information for future HEEs. A broader conclusion is that novel oral medications, such as the first oral PI, have a significant potential for reducing administration-related costs of subcutaneous or intravenous PIs. PMID: 30644325 [PubMed - as s...
Source: Journal of Medical Economics - January 17, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
CONCLUSIONS: The 4- and 5-state versions of the PSM cohort model estimated in this study deviate from the standard 3-state approach to better capture I-O response patterns. Markov and PLS approaches, by modeling state transitions explicitly, could be more informative in understanding I-O immune response, the PLS particularly so by reflecting heterogeneity in treatment response. However, both require a number of assumptions to capture the immune response effectively. Better I-O representation with surrogate endpoints in future clinical trials could yield greater model validity across all models. PMID: 30638416 [PubMed -...
Source: Journal of Medical Economics - January 15, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
CONCLUSIONS: In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and potentially cost-saving alternative to VKA in the Netherlands. PMID: 30614320 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 8, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
Authors: Trantham L, Sikirica MV, Candrilli SD, Benson VS, Mohan D, Neil D, Joshi AV Abstract AIMS: Muscle weakness (MW)-attributable healthcare resource utilization (HCRU) and costs in patients with chronic obstructive pulmonary disease (COPD) have not been well-characterized in United States insurance claims databases. The primary objective of this study was to estimate HCRU in patients with evidence of COPD with and without MW diagnosis codes. MATERIALS AND METHODS: This retrospective analysis used the MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits dat...
Source: Journal of Medical Economics - December 26, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
CONCLUSIONS: Models assumed independent, non-recurrent outcomes and were restricted to medical costs directly associated with the trial-reported events. The reductions in CVD events in T2DM patients reported for both CANVAS and EMPA-REG project to a positive cost avoidance for these events in an MCO population. The analysis did not include an assessment of the impact on total cost, as the costs associated with adverse events, drug utilization or other clinical outcomes were not examined. PMID: 30575426 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 23, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Measurement of patient-reported outcomes. 1: The search for the Holy Grail.
Authors: McKenna SP, Heaney A, Wilburn J, Stenner AJ Abstract Patient-reported outcome measures (PROMs) are used to collect information directly from patients. They may cover several different types of outcomes ranging from symptoms, functioning, utility, satisfaction through to quality of life (QoL). They generally consist of self-completed questionnaires that can be administered by means of hard copies or in a range of electronic formats. PROMs vary considerably in terms of the constructs they assess, the care with which they are developed and their scientific quality. However, none of the PROMs available approac...
Source: Journal of Medical Economics - December 19, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Measurement of patient-reported outcomes. 2: Are current measures failing us?
This article argues that higher quality PROM development is needed if meaningful and valid PRO measurement is to be achieved. It describes the current state of PROM development, shows that published reviews of PROMs adopt inappropriate criteria for judging their quality and illustrates how the use of traditional PROMs can lead to incorrect (and possibly dangerous) conclusions being drawn about the efficacy of interventions. PMID: 30556787 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 19, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.
Authors: Choon JW, Wu DB, Chong HY, Lo WT, Chong CS, Chung WS, Chui EM, Tomlinson B, Lee VW, Lee SC, Lee KK Abstract BACKGROUND: Very few data are available to demonstrate the economic benefit of early paliperidone palmitate once-monthly long-acting injectable (PP1M) treatment in patients with schizophrenia or schizoaffective disorder. METHODS AND MATERIALS: We have retrospectively compared the health care utilization and associated costs of pre and post PPIM treatment in 413 patients with schizophrenia or schizoaffective disorder recruited from 3 major public hospitals providing psychiatric services in Hong Ko...
Source: Journal of Medical Economics - December 19, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in IRAN.
CONCLUSIONS: According to the results of this study, the cost-effectiveness and cost-utility of fingolimod were higher than those of natalizumab. Therefore, it is recommended that treatment with fingolimod be the first priority of second-line treatment for MS patients, and policy makers and health managers are encouraged to make efforts in order to increase insurance coverage and reduce the out-of-pocket payments of these patients. PMID: 30561242 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 19, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Hospital patients with severe wounds: early evidence on the impact of Medicare payment changes on treatment patterns and outcomes.
CONCLUSIONS: The new LTCH payment policy is associated with no changes in Medicare spending and mortality but higher readmissions and post-discharge sepsis rates among severe wound patients with a high likelihood to use an LTCH. PMID: 30547697 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 16, 2018 Category: Health Management Tags: J Med Econ Source Type: research